Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for XOMA Corporation (XOMA:NASDAQ), powered by AI.
XOMA Corporation is currently trading at $41.78. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for XOMA Corporation on Alpha Lenz.
View XOMA Corporation's valuation metrics on Alpha Lenz.
“XOMA Corporation's ROE is 38.2%. Explore profitability and growth together.”
Ask for details →XOMA Corporation is an innovative biotechnology company that specializes in the discovery, development, and licensing of antibody therapeutics. The primary aim of the company is to license its drug candidates and proprietary platform to other pharmaceutical companies, thereby harnessing its expertise in antibody engineering. This enables partnership opportunities that advance therapeutic solutions through various stages of clinical trials without the direct burden of commercialization. XOMA focuses heavily on the fields of oncology and immunology, impacting how diseases in these sectors are approached and treated. The company is significant in the biotechnology market as it provides critical resources and innovations that fuel the development pipeline of larger pharmaceutical enterprises. Based in Emeryville, California, XOMA leverages its comprehensive portfolio of antibody-based therapeutics to play a pivotal role in advancing the medical and health industries through collaborations and strategic partnerships.
“XOMA Corporation's ROE is 38.2%. Explore profitability and growth together.”
Ask for details →XOMA Corporation (ticker: XOMA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees.
The current price is $41.78 with a P/E ratio of -x and P/B of -x.
ROE is 38.24% and operating margin is 97.63%. Annual revenue is $12M.